Intravenous alteplase is one of the most effective medicines to improve prognosis for acute ischemic stroke patients. The effect of intravenous thrombolysis of stroke patients with different severity varies a lot. There comes a new statement for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke from the American Heart Association/American Stroke Association in February, 2016. In the statement it recommended to use intravenous alteplase for severe stroke patients or mild stroke patients who has disability risk within 3 hours. It should be cautious for patients with mild stroke and without disability risk to use alteplase within 3 hours.%急性缺血性卒中患者使用阿替普酶静脉溶栓治疗是改善预后最有效的方法。不同严重程度的卒中患者其溶栓的效果不尽相同。2016年2月新发表的声明中对不同严重程度的卒中患者使用阿替普酶静脉溶栓提出了新的观点，建议对于症状严重的，或者症状轻微但是有残疾可能的卒中患者，应当在症状开始3 h内静脉使用阿替普酶，而在症状出现3 h内对于症状轻微且判断没有致残风险的卒中患者，静脉阿替普酶治疗是待考虑的。
展开▼
